# Sources — Irène Joliot-Curie

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

Accessed November 5, 2026. The canonical source metadata and claim links are in `case.json`.

## Historical evidence

1. “Irène Joliot-Curie – Biographical,” from *Nobel Lectures, Chemistry 1922-1941*. NobelPrize.org. Supports her birth in Paris on September 12, 1897; her service as a nurse radiographer in the First World War; her doctorate in 1925 on the alpha rays of polonium; her marriage to Frédéric Joliot in 1926; her work on natural and artificial radioactivity; her appointment as Undersecretary of State for Scientific Research in 1936; that the couple had a daughter and a son; and her death on March 17, 1956. https://www.nobelprize.org/prizes/chemistry/1935/joliot-curie/biographical/
2. “Irène Joliot-Curie (1897-1956).” AtomicArchive.com. Supports the joined surnames, the 1935 Nobel Prize in Chemistry for the synthesis of new radioactive elements, the professorship from 1937, the 1938 work on neutrons and heavy elements, her directorship of the Radium Institute from 1946, six years as a commissioner for atomic energy and the first French atomic pile in 1948, the plans for Orsay, and her death in Paris on March 17, 1956, “from leukemia contracted in the course of her work.” https://atomicarchive.com/resources/biographies/irene-curie.html
3. “Irene Joliot-Curie” (profile). Atomic Heritage Foundation, National Museum of Nuclear Science and History. Supports her work at mobile field hospitals operating X-ray machines in the First World War, the discovery of artificial radioactivity by exposing aluminum foil to alpha particles, her recovery from tuberculosis in Switzerland during the Second World War and bringing her children there in 1944, and her death of leukemia “caused by years of radiation exposure.” It gives her age at death as 59; the other sources and her dates give 58. https://ahf.nuclearmuseum.org/ahf/profile/irene-joliot-curie/
4. “Scientist of the Day: Irène Joliot-Curie.” Linda Hall Library, March 17, 2016. Supports her death on March 17, 1956, at 58, and that her leukemia “is usually attributed to her over-exposure to x-rays during the war, and to radioactive chemicals during her life of research” (CLM-0012). https://www.lindahall.org/about/news/scientist-of-the-day/irene-joliot-curie
5. Zielinski S. “Six Secrets of Polonium.” *Smithsonian Magazine*. Supports that in 1946 a capsule of polonium exploded on her laboratory bench (CLM-0010), and that this “may have been responsible for her death, 10 years later, of leukemia” (CLM-0011). https://www.smithsonianmag.com/science-nature/six-secrets-of-polonium-94821613/
6. “Irène Joliot-Curie,” illustration page for lecture 29 of the course *Science, civilization and society*, hosted by the Indian National Centre for Ocean Information Services and citing the *Encyclopaedia Britannica* and the Nobel e-Museum. Supports that she had always been of unstable health, with regular trips to the countryside; that her health declined visibly shortly after 1950; and that a stay in the mountains in 1956 brought no improvement. https://incois.gov.in/Tutor/science+society/lectures/illustrations/lecture29/icurie.html
7. “The Radium Institute (1919-1934),” online exhibit, American Institute of Physics Center for History of Physics (the page title, which names her mother, is shortened here). Supports her mother’s death on July 4, 1934, and the sanatorium director’s report of “an aplastic pernicious anemia of rapid, feverish development,” with bone marrow probably “injured by a long accumulation of radiations” (CLM-0016). https://history.aip.org/exhibits/curie/radinst3_text.htm
8. HISTMED Master Roster v3. Internal project source; not treated as independent corroboration.

## Clinical guidance

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia, Version 5.2026 (version confirmed on the NCCN page on November 5, 2026; the guideline text requires a login and was not read directly). https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1411
2. Döhner H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. *Blood* 2022 (PMID 35797463). Abstract read: revised genetic risk classification, response criteria and treatment recommendations. https://pubmed.ncbi.nlm.nih.gov/35797463/
3. Khoury JD, et al. The 5th edition of the WHO Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. *Leukemia* 2022 (PMID 35732831). Full text read in Europe PMC: myeloid neoplasms post cytotoxic therapy require “a documented history of chemotherapy treatment or large-field radiation therapy for an unrelated neoplasm.” https://pubmed.ncbi.nlm.nih.gov/35732831/
4. Arber DA, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias. *Blood* 2022 (PMID 35767897). Abstract read; the full text could not be retrieved. https://pubmed.ncbi.nlm.nih.gov/35767897/
5. DiNardo CD, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia (VIALE-A). *N Engl J Med* 2020 (PMID 32786187). https://pubmed.ncbi.nlm.nih.gov/32786187/
6. NCCN Prevention and Treatment of Cancer-Related Infections, and Taplitz RA, et al. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy (ASCO and IDSA, 2018; PMID 29461916). https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1457 and https://pubmed.ncbi.nlm.nih.gov/29461916/
7. Sanders JJ, et al. Palliative Care for Patients With Cancer: ASCO Guideline Update (2024; PMID 38748941). https://pubmed.ncbi.nlm.nih.gov/38748941/
8. Carson JL, et al. Red Blood Cell Transfusion: 2023 AABB International Guidelines (PMID 37824153), and Kaufman RM, et al. Platelet transfusion: a clinical practice guideline from the AABB (2015; PMID 25383671). https://pubmed.ncbi.nlm.nih.gov/37824153/ and https://pubmed.ncbi.nlm.nih.gov/25383671/
9. Hwang JP, et al. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update (2020; PMID 32716741). https://pubmed.ncbi.nlm.nih.gov/32716741/
10. Hesketh PJ, et al. Antiemetics: ASCO Guideline Update (2020; PMID 32658626). https://pubmed.ncbi.nlm.nih.gov/32658626/
11. 10 CFR 19.13, Notifications and reports to individuals (Electronic Code of Federal Regulations): licensees must give workers their dose reports on request. https://www.ecfr.gov/current/title-10/chapter-I/part-19/section-19.13
12. 29 CFR 1910.1096, Ionizing radiation (OSHA): paragraph (n) requires employers to keep exposure records and tell employees their exposure at least yearly; paragraph (o) requires a report to a former employee within 30 days of a request. https://www.osha.gov/laws-regs/regulations/standardnumber/1910/1910.1096
13. U.S. Preventive Services Task Force recommendations, the CDC Adult Immunization Schedule by Age, and the Medicare Preventive Services reference (Aether Forge, 2026). https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations, https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-age.html and https://patrickrutledge.github.io/preventative_services/

The CMID has no monograph for acute myeloid leukemia, so it is not cited; the specialty guidelines above are used instead.

## Editorial resolutions

- **Her mother is not named.** Her mother has her own record in this panel, so this record never uses her name or her other names. She is described as “her mother, a physicist who also worked with radioactive materials,” and her death from aplastic anemia attributed to radiation is family history (FH-001, CLM-0016, **D**). The AIP exhibit’s title, which contains her name, is shortened in the source list. Her father, Pierre Curie, is named only in CLM-0001. The record was searched for her mother’s given name before the final build.
- **Recent-death rule.** She died in 1956, so the rule does not apply. No claim is marked sensitive. Her death is recorded in one sentence (CLM-0015) and not used in the modern episode.
- **Children and other relatives.** Her daughter and son are recorded only as documented history (CLM-0006), without names, because they may be living. They play no part in the modern episode: no donor testing, decisions, statements or health facts are attributed to them or to any other relative. The transplant plan uses an unrelated donor search. Frédéric Joliot appears only in claims about their shared work.
- **The type of her leukemia is not documented.** The fetched sources say only “leukemia.” The modern subtype is synthetic. Its attribution to radiation is recorded as **R**: Smithsonian’s suggestion that the 1946 accident may have been responsible (CLM-0011, possible), and the usual attribution to X-ray and radioactive-material exposure over her career (CLM-0012, probable). The accident itself is **D**, probable, from a single popular-science source; no dose estimate is documented, and none is invented.
- **Choosing the modern diagnosis and subtype (judgment call).** Acute myeloid leukemia was chosen, as the brief suggested, because the leukemias most clearly linked to ionizing radiation are myeloid, and her mother’s marrow failure gives the family history its teaching point; nothing in the sources favors a different blood cancer. The genetics chosen (a complex karyotype with del(5q), -7 and -17, and a TP53 mutation at 41 percent) are those typical of radiation-associated and therapy-related myeloid neoplasms. Classification: WHO 2022 “AML, myelodysplasia-related” (defined by the complex karyotype) and ICC 2022 “AML with mutated TP53”; ELN 2022 adverse. Neither the WHO “post cytotoxic therapy” label nor the ICC “therapy-related” qualifier is applied, because the WHO text requires earlier chemotherapy or large-field radiotherapy for an unrelated neoplasm and her exposure was occupational; the leukemia is described as following occupational exposure to ionizing radiation, with Z57.1 on the problem list. The ICC text was read only as an abstract, so the ICC part of this reasoning rests on the brief’s framing and should be checked by the reviewer.
- **Choosing the treatment (judgment call).** Azacitidine with venetoclax rather than intensive induction, because she is unfit for intensive induction under the VIALE-A criteria (ECOG 2 at the start of treatment and a DLCO of 58 percent of predicted from old tuberculous scarring, HCT-CI 3), because intensive chemotherapy gives poor results in TP53-mutated AML, and by her own informed choice. Intensive induction and trials were discussed. Venetoclax is given at 70 mg after the ramp-up because posaconazole is a strong CYP3A inhibitor; it is stopped at day 22 after a leukemia-free marrow and cycle 2 uses 21 days. The response at day 33 is ELN 2022 complete remission with partial hematologic recovery, with measurable residual disease detectable, leading to a plan for a reduced-intensity matched unrelated donor transplant. The episode ends before transplant; it does not imply a cure.
- **Tuberculosis.** The sources document tuberculosis with recovery in Switzerland during the Second World War (CLM-0008); the year it began is not documented in a fetched source, and a 1930s sanatorium history seen in a search summary was not confirmed and is not used. The modern episode records treated pulmonary tuberculosis with apical scarring and reduced gas transfer; the treatment and the lung findings are synthetic.
- **Index age and dates.** The index visit on September 14, 2026 maps to September 14, 1955, when she was 58. The synthetic date of birth is September 12, 1968 (shift 71 years). All visits (September 16, September 28, October 8, October 19, October 26, and October 30, 2026) map to the autumn of 1955, after the decline in her health that began after 1950 (CLM-0013) and before the 1956 mountain stay (CLM-0014), whose dates are not documented; no fetched source places her elsewhere in that autumn. The episode is a modern teaching record, not a claim about where she was or what treatment she had. Past medical history includes only events before the index date; the 1956 events are linked only to later timeline events.
- **Occupational health.** The occupational history, the written request for her dosimetry and bioassay records, and the employer’s duty to keep and release them (10 CFR 19.13; 29 CFR 1910.1096) are synthetic modern content anchored to her documented work and the 1946 accident. The records never arrive within the episode; nothing about their contents is invented.
- **Sources not used.** NobelPrize.org was read through a downloaded copy because the site refused automated fetching. Britannica returned an error page and Wikipedia was not used; a German school lexicon was read but not cited. The INCOIS course page is the only fetched source for the decline after 1950 and the 1956 mountain stay; this should be checked by the reviewer.
- **Synthetic content.** All visits, laboratory values, vital signs, marrow and genetic results, imaging, lung function, the ECGs, survey scores, medicines and doses, transfusions, the sick visit, her height (163 cm) and weights, her household and work routine, her preferences, and the health care agent are synthetic. Qualitative results (flow cytometry, cytogenetics, molecular panel, measurable residual disease, chest X-ray, hepatitis and HIV tests, posaconazole level) appear only in the note text.
- **Sick visit.** Nausea, vomiting and constipation on day 11 of cycle 1, chosen because they are common with azacitidine and venetoclax and can be managed in clinic when there is no fever. It teaches checking the QTc before ondansetron in a patient on posaconazole and levofloxacin, replacing potassium, avoiding rectal medicines in neutropenia, and prophylactic platelet and single-unit red cell transfusion. Fever would have meant the emergency department, so a febrile illness was not used. It implies no real diagnosis.
- **Preventive visit.** A periodic adult preventive visit at 58 during induction (CPT 99396 with 99497 in plain text). Judgment calls: inactivated influenza vaccine given and COVID-19 vaccine ordered during therapy; pneumococcal, recombinant zoster, Tdap and hepatitis B vaccines deferred until after therapy or to the transplant revaccination schedule; breast, cervical and colorectal screening and lipid assessment deferred during induction, with the reasons; HIV and hepatitis C counted as done before therapy; advance care planning records her own goals and an unnamed agent.
- **Focused visits.** The four chronic-care follow-ups (two days with the consultation and marrow, the results review and day 1, day 22, and day 33) are documented as focused visits on the NCCN AML guideline, ELN 2022, the WHO and ICC 2022 classifications, VIALE-A, the NCCN infections and ASCO/IDSA febrile neutropenia guidance, the AABB transfusion guidelines, the ASCO palliative care guideline, and the federal dose-record rules. One deviation is recorded instead of an invented result: the posaconazole trough level due after about a week of dosing was not drawn; no harm resulted (no fever or fungal infection, normal liver tests, QTc 446 ms), and the level was drawn with the next blood count and added to the cycle order set. The measurable residual disease marrow after cycle 2 and the dose records are due after the episode ends.
- **Consultation.** The hematology/oncology referral and the consultation by Tobias Engquist-Mensah, MD (a fictional consultant), on the day of the two-day visit, are **S**. The consultant answers the six referral questions before the genetic results are known, with recommendations conditional on them, and these agree with what happened afterwards: adverse genetics and unfitness by the VIALE-A criteria leading to azacitidine with venetoclax at 70 mg with posaconazole, admission for the ramp-up, a day-22 marrow with venetoclax held, irradiated single-unit transfusion and prophylactic platelets below 10, posaconazole, acyclovir and levofloxacin, an unrelated donor search, palliative care from the first cycle, and the written request for dose records.
